IATDMCT Congress 2017 Poster Presentations

To get the latest update, please clear or refresh your web browser's cache.
*i.e. Google Chrome: Ctr + F5 keys

P27-1: Anti-infective drugs (6): Anti-MRSA and antifungals

# Presentation Title Name Country Affiliation
1 Population pharmacokinetic analysis of teicoplanin using serum cystatin Cto predict renal clearance Hidefumi Kasai Japan Certara G.K.
2 Pharmacokinetic/pharmacodynamic evaluation of teicoplanin againstStaphylococcus aureus in murine thigh infection model Erika Watanabe Japan Kagoshima University
3 An effective case of replacement of teicoplanin with arbekacin fortreatment of methicillin-resistant Staphylococcus aureus iliopsoas abscess YoshimasaTsuchishita Japan Maizuru Kyosai Hosipital
4 Estimation of the duration to reach peak arbekacin concentration byMonte Carlo simulation KazunoriYamaguchi Japan Kagawa University Hospital
5 Precision linezolid dosing: save lives, save money! Deborah JanetMarriott Australia St. Vincent's Hospital
6 Prediction of thrombocytopenia associated with linezolid based onpharmacokinetic-pharmacodynamic simulation Tetsushu Onita Japan Shimane University Hospital
7 ARK linezolid assay for the Beckman AU480 automated clinical chemistryanalyzer Kenneth Kasper United States ofAmerica ARK Diagnostics Inc.
8 False prolongation of prothrombin time in the presence of high bloodconcentration of daptomycin TomoyukiYamada Japan Osaka Medical College Hospital
9 Development of novel LCMSMS assay for therapeutic drug monitoring ofeight antifungal drugs in human serum Jie Xing Singapore Shimadzu (Asia Pacific) Pte Ltd.
10 A validated easy HPLC-MS method for quantification of isavuconazole andother four triazole antifungal drugs in human plasma Antonio D'Avolio Italy University of Turin

P27-2: Anti-infective drugs (7): Antifungals

# Presentation Title Name Country Affiliation
1 Evaluation of the ARKTM Voriconazole ll immunoassay on the AbbottArchitecttm analyser Maria Outeda-Macias Spain A Coruna University Hospital Complex
2 Individualized medication of voriconazole: a practice guideline of thedivision of therapeutic drug monitoring, Chinese Pharmacological Society Suodi Zhai China Peking University Third Hospital
3 Therapeutic drug monitoring of voriconazole in Chinese patients withinvasive fungal infections in West China Hospital Jiang-Tao Tang China West China Hospital of Sichuan University
4 Therapeutic drug monitoring and individualized dosing of voriconazole infungal-infected Korean patients Yewon Choi South Korea Seoul National University
5 Voriconazole TDM based on both unchanged drug and metaboliteconcentrations in Japanese patients Akari Shigemi Japan Kagoshima University Hospital
6 Impact of CYP2C19 genotype and liver function on voriconazolepharmacokinetics in renal transplant recipients Miao Yan China The Second Xiangya Hospital, Central SouthUniversity
7 Usefulness of therapeutic drug monitoring of voriconazole in patients withliver cirrhosis (Child-Pugh class C) Takehiro Yamada Japan Hokkaido University Hospital
8 Computerised optimal fluconazole dose selection improves early targetattainment in critically ill patients Indy Sandaradura Australia Westmead Hospital
9 Effective plasma concentrations of itraconazole and its active metabolitefor pulmonary aspergillosis Yaeko Nakamura Japan Doshisha Women's College of Liberal Artsand National Hospital Organization MinamiKyoto Hospital
10 Intermittent prophylactic high dose administration of micafungin in acohort of children undergoing hematopoietic stem cell transplantation(HSCT) MariadelfinaMolinaro Italy Fondazione IRCCS Policlinico San Matteo

P27-3: Anti-infective drugs (8): Antiviral

# Presentation Title Name Country Affiliation
1 Economic burden of inappropriate use of antibiotics in viral diseases: thecase of RSV infection Jefferson Buendia Colombia University of Antioquia
2 A simple, fast and high throughput quantitative method for thesimultaneous determination of dolutegravir, atazanavir, darunavir,efavirenz, lopinavir and ritonavir in human plasma using ESI+ LC-MS/MS Antero VieiraSilva Sweden Karolinska University Laboratory
3 Methadone reduced nevirapine pharmacokinetic parameters in patientswith HIV Suzana Mustafa Malaysia Universiti Sains Malaysia
4 Effects of cobicistat and ritonavir on tenofovir plasma concentrations Dario Cattaneo Italy Luigi Sacco University Hospital
5 Interaction between darunavir and etravirine is partly mediated by CYP3A5polymorphism Vincent Haufroid Belgium Universite catholique de Louvain
6 Population pharmacokinetics of ganciclovir in critically ill patients Reinier van Hest TheNetherlands Academic Medical Center
7 Singel-dose pharmacokinetics of acyclovir and its principal metabolite 9-carboxymethoxymethylguanine (CMMG) in subjects with normal orimpaired renal function and in hemodialysis patients Anders Hellden Sweden Karolinska Institutet
8 Effectiveness of acyclovir prophylaxis for varicella zoster virus infectionafter hematopoietic stem cell transplantation: a systematic review andmeta-analysis Yuko Shimosato Japan Yokohama City University

P27-4: Cardiovascular drugs (1)

# Presentation Title Name Country Affiliation
1 A case of significantly prolonged PT-INR after use of miconazole gelledpreparation during warfarin therapy Ayumu Nagamine Japan Gunma University
2 Green tea extract and (-)-epigallocatechin-3-gallate greatly affectpharmacokinetic of rosuvastatin in rats Chenrong Huang China The First Affiliated Hospital of SoochowUniversity
3 The effect of amiodarone on warfarin anticoagulation: a register-basednationwide cohort study involving the Swedish population Johan Holm Sweden Karolinska Institutet, Karolinska UniversityHospital Huddinge
4 Pharmacokinetics and hypoglycemic effect of cibenzoline in treatmentwith losartan or metoprolol in rats Yuna Yoshino Japan Osaka University of PharmaceuticalSciences
5 Serum digoxin concentration and mortality in patients with heart failure Toshinori Hirai Japan Tokyo Women's Medical UniversityHospital
6 Cardiovascular drug monitoring using quantitative LC-HRMS analysis ofself-collected micro-volume blood samples Sangeeta Tanna United Kingdom De Montfort University

P27-5: Cardiovascular drugs (2)

# Presentation Title Name Country Affiliation
1 Effect of angiotensin II receptor blockers on serum levels ofepoxyeicosatrienoic acids Yuka Kato Japan Hokkaido Pharmaceutical University
2 Simultaneous determination of metoprolol, amlodipine, canrenone andhydrochlorothiazide via LC-MS/MS in patients with therapy-refractoryarterial hypertension Carsten Mueller Germany University Hospital of Cologne
3 Decrease of digoxin level due to concurrent use of rifampicin: case report Jun Gi Hwang South Korea Seoul National University
4 Screening and quantification method for antihypertensive agents using LC-MS/MS: a valuable tool for medication adherence assessment Arjen Punt TheNetherlands University Medical Center Utrecht
5 Switching from febuxostat to topiroxostat: efficacy, tolerability and serumconcentration in hemodialysis patients SatoruMitsuboshi Japan Kaetsu Hospital
6 Population pharmacokinetics of milrinone in newborns and infants aftercardiac surgery Tomoyuki Mizuno United States ofAmerica Cincinnati Children's Hospital MedicalCenter
7 Determination of homocysteine in human plasma / serum using LC-MS8060 Changkun Li China Shimadzu (China) CO., LTD.

P27-6: Clinical toxicology (2)

# Presentation Title Name Country Affiliation
1 Acryloylfentanyl: identification in seized powder and a fatal forensic case Torben Breindahl Denmark North Denmark Regional Hospital
2 Performance of an on-site test for gamma-hydroxybutyric acid (GHB) inpatients presented at the emergency department Thomas Smits TheNetherlands OLVG Hospital
3 Changing trends in substance abuse: analysis of lab test results frompatient cohort at The National Rehabilitation Center, Abu Dhabi, U.A.E. AbuelgasimElrasheed AhmedAlhassan United ArabEmirates National Rehabilitation Center
4 Qualitative/quantitative analysis and the pharmacokinetic characterizationof drug-induced intoxication cases in clinical settings Motozumi Ando Japan Kobe Gakuin University
5 A response to the rapid emergence of deadly designer opioids in the U.S. MatthewMcMullin United States ofAmerica NMS Labs
6 Treatment of a severe amlodipine auto-intoxication Charles J. C.Geerlings TheNetherlands Franciscus Gasthuis & Vlietland
7 Methods of identification of AB-CHMINAKA in case of expert researches Fazliddin Jalilov Uzbekistan Tashkent Pharmaceutical Institute
8 Data dependent or data independent acquisition: evaluation of SWATH forclinical drug testing Kara L. Lynch United States ofAmerica University of California San Francisco
9 A high-throughput solution for therapeutic drug monitoring with LC-MS/MS ? 132 drugs on one column Klaus MartinKnirsch Germany Recipe GmbH

P27-7: Assay

# Presentation Title Name Country Affiliation
1 Using MRM spectrum mode in quantitative clinical toxicological screening ToshikazuMinohata Japan Shimadzu Corporation
2 Toxicological screening for over 1000 compounds in whole blood samplesusing LC-MS/MS in MRM spectrum mode Jun Watanabe Japan Shimadzu Corporation
3 Experience of using LC HRMS in full scan and PRM mode for reliable multicomponent urine drug screening NiclasStephanson Sweden Karolinska University Hospital
4 Clinical significance of N-acetylcysteine interferes with the trinder reactionbased assays Yusheng Zhu United States ofAmerica Pennsylvania State University HersheyMedical Center
5 Method development matrix effects: a case study Autumn Breaud United States ofAmerica Johns Hopkins University
6 Development and validation of an ICP-MS method to quantitativelydetermine cobalt in volumetric absorptive microsampling (VAMS) devicesfor the follow-up of metal-on-metal prosthesis patients Sara Capiau Belgium Ghent University
7 Measurement of nicotine, cotinine and OH-cotinine in exhaled breath withLC-MS/MS Shahid Ullah Sweden Karolinska University Hospital
8 Drug sensor using molecularly imprinted polymer grafted on graphitepaste electrode Yasuo Yoshimi Japan Shibaura Institute of Technology
9 LC-MS/MS simultaneously analyze 12 kinds of TDM compounds Meiying Han China Shimadzu (China) CO., LTD.
10 Fully automated LC-MS/MS platform for drugs quantitation in serumsamples Isabel TeresaCabruja Italy Shimadzu Corporation

P27-8: Assay and monitoring

# Presentation Title Name Country Affiliation
1 A sensitive LC-MS/MS method for quantification of fluticasone propionatein human plasma after intranasal administration Hiromi Shibasaki-Hirano Japan Tokyo University of Pharmacy and LifeSciences
2 A HPLC-DAD method for the determination of global methylation inperipheral human blood Marina VenzonAntunes Brazil Universidade Feevale
3 High-sensitivity determination of underivatized estradiol in human serumby a validated LC-MS/MS method Dobin Svinarov Bulgaria Alexander Hospital, Medical University ofSofia
4 Determination of iodine element in urine sample by inductively coupledplasma-mass spectrometry Rongyin Gai China Shimadzu (China) CO., LTD.
5 Clinical monitoring of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 byLC-MS/MS Xin Deng China Shimadzu (China) CO., LTD.
6 Quantitative analysis of vitamin D2 and D3 using SFC-MS/MS SigridBaumgarten Germany SHIMADZU Europa GmbH
7 A new LC-MS/MS method for determination of vitamin K1 and vitamin K2(MK-4, MK-7) in serum Eva Klapkova Czech Republic Charles University and University HospitalMotol
8 The real time inhalation flow pattern monitoring system contributes toadequate inhalation patterns of soft mist inhaler co-prescribed with drypowder inhaler Hiroyoshi Koide Japan Kyoto Pharmaceutical University
9 Evaluation of Tof-MRM for the analysis of illicit drug substances Masayo Yabu Japan Nihon Waters KK
10 Metabolomics deciphering therapeutic effects and mechanism of naturalproducts on metabolic diseases Li-Heng Pao Taiwan Chang Gung University of Science andTechnology

P27-9: Pharmacokinetics and PK/PD

# Presentation Title Name Country Affiliation
1 Chromatographic determination of serum eltrombopag concentration forthe therapeutic drug monitoring in patients with idiopathicthrombocytopenic purpura NaoyaYanagimachi Japan University of Tsukuba Hospital andUniversity of Tsukuba
2 Effect of sampling time on prediction accuracy of serum drugconsentrations Syoyo Tanemura Japan Musashino University
3 KinPop++ enables clinicians to easily develop new PK/PD populationmodels for use in the MwPharm++ therapeutic drug management (TDM)software using an iterative two-stage bayesian (ITSB) technique Jiri Potucek Czech Republic MEDIWARE A.S.
4 Population pharmacokinetics of arginine glutamate in healthy Chinesevolunteers Jing Wang China Tongji Hospital of Tongji Medical College,Huazhong University of Science andTechnology
5 PK/PD analysis of postoperative nausea and vomiting in Japanese patientsadministered epidural fentanyl Saeri Goto Japan Gifu Pharmaceutical University
6 Febuxostat exposure-response model in patients with renal dysfunction Daiki Hira Japan Shiga University of Medical ScienceHospital
7 Comparison of therapeutic efficacy of brand-name allopurinol and itsgeneric medicine by population pharmacodynamic analysis based onelectronic medical records Takamitsu Ogata Japan Kyushu University
8 Benchmark dose analysis for safety assessment in pharmaceuticaldevelopment Antero VieiraSilva Sweden Karolinska University Laboratory
9 Quantitative prediction of drug removal rate by hemodialysis based on thepermeation clearance of hemodialyzer TakehitoYamamoto Japan The University of Tokyo
10 Serum concentrations of sulfate and glucuronide conjugates of Ritodrinein twin pregnancy Mayuko Soma Japan Tenshi Hospital

P27-10: Pharmacokinetics and pharmacogenetics

# Presentation Title Name Country Affiliation
1 Modeling drug transfer over the mammary gland using physicochemicalparameters and active transport as descriptors Peter Ter Horst TheNetherlands Isala
2 Mesalazine and foetal anaemia ? a case report StaffanRosenborg Sweden Karolinska University Hospital
3 Pharmacokinetics and pharmacogenetics of metformine in patients withtype 2 diabetes mellitus Silvia Romano Mexico Universidad Autonoma de San Luis Potosi
4 The use of next-generation sequencing (NGS) data in pharmacogenetics: asoftware for allele calling based on star nomenclatures Jean-BaptisteWoillard France CHU Limoges, Univ Limoges
5 Pharmacogenetics-based personalized therapy: levels of evidence andrecommendations from the French national network of pharmacogenetics(RNPGx) regarding 4 major therapeutic domains Jean-BaptisteWoillard France CHU Limoges Univ Limoges
6 In vivo phenotyping for CYP3A by a single-point determination of plasmaconcentration ratio of endogenous 6β-hydroxycortisol to cortisol Ryohei Hirano Japan Tokyo University of Pharmacy and LifeSciences
7 Phenoconversion of CYP3A in chronic renal failure; what is the factorinvolved? Yosuke Suzuki Japan Oita University Hospital
8 Inhibitory effects of flavonoid-containing vegetables on CYP3A4 activity inrecombinant CYP3A4 and LS180 cells MasayukiTsujimoto Japan Kyoto Pharmaceutical University
9 In search of objective criteria for judging results of TDM proficiency tests PeterZweipfenning TheNetherlands SKML, section KKGT
10 Education in clinical pharmacokinetics: clearance and elimination rateconstant parameterizations are equally valid Roger WoodhamJelliffe United States ofAmerica USC Keck School of Medicine, Children'sHospital of Los Angeles